inverse agonist


Also found in: Dictionary, Thesaurus, Encyclopedia, Wikipedia.
Related to inverse agonist: Partial agonist

inverse agonist

A drug that binds the same cellular receptors as an agonist, but elicits a negative, or opposing cellular response.
See also: agonist
References in periodicals archive ?
3) Inverse agonists bind to the same receptor as a normal neurotransmitter or agonist but induce the opposite effect (rather than just preventing neurotransmitter or agonist actions by blocking their interaction with the receptor).
We applaud Arena for discovering and advancing a potent, selective and potential best-in-class 5-HT2A inverse agonist, and we look forward to consummating the development and commercialization of nelotanserin.
Temanogrel is an inverse agonist of the serotonin 2A receptor intended for the treatment of thrombotic diseases, and has completed single- and multiple-ascending dose Phase 1 trials in healthy volunteers.
Pimavanserin tartrate is a novel, potent, and selective 5-HT2A inverse agonist that ACADIA discovered and is developing as a treatment for PDP.
In a poster presentation titled "Pimavanserin, a 5-HT2A Receptor Inverse Agonist, Improves Antipsychotic Efficacy and Cognitive Properties of Atypical Antipsychotic Drugs," ACADIA researchers present data showing pimavanserin improves the activity of a number of the most commonly used atypical antipsychotic agents in animal models predictive of antipsychotic efficacy.
Pimavanserin tartrate, previously referred to as ACP-103, is a novel, potent, and selective 5-HT2A inverse agonist that ACADIA discovered and is developing as a treatment for PDP.
Pimavanserin tartrate (previously referred to as ACP-103) is a novel, potent and selective 5-HT2A inverse agonist that ACADIA discovered and is developing as a co-therapy for schizophrenia and as a treatment for Parkinson's disease psychosis and sleep maintenance insomnia.
APD916, a potent and selective inverse agonist of the histamine H3 receptor, is Arena's internally discovered drug candidate for the treatment of narcolepsy and cataplexy.
Nasdaq:ACAD) today announced positive top-line results from its Phase II schizophrenia co-therapy trial with ACP-103, ACADIA's proprietary and selective 5-HT2A inverse agonist.
APD791 is a novel, orally available and selective inverse agonist, or inhibitor, of the 5-HT2A serotonin receptor.
1]-receptors exist in equilibrium, responding to histamines (agonists) and inverse agonists (antihistamines).
This basal activity can be suppressed by odorants functioning as inverse agonists.